RNAC

Cartesian Therapeutics, Inc.

Healthcare
Biotechnology
$241M market cap

Forecast run · Sep 14, 2026Upside rank 558 of 3,136

Model Signal

ForecastQ Daily Probabilities

54.1%

40.9%

35.9%

Analyst Consensus

Recommendation2.20/5 Buy

Last price$8.19

Price target$25.00

Implied move+205.3%

Analysts10

ForecastQ Portfolios

RNAC is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.